Unknown

Dataset Information

0

T-cell acute lymphoblastic leukemia.


ABSTRACT: T-cell acute lymphoblastic leukemia (T-ALL) is biologically distinct from its B lymphoblastic (B-ALL) counterpart and shows different kinetic patterns of disease response. Although very similar regimens are used to treat T-ALL and B-ALL, distinctions in response to different elements of therapy have been observed. Similar to B-ALL, the key prognostic determinant in T-ALL is minimal residual disease (MRD) response. Unlike B-ALL, other factors including age, white blood cell count at diagnosis, and genetics of the ALL blasts are not independently prognostic when MRD response is included. Recent insights into T-ALL biology, using modern genomic techniques, have identified a number of recurrent lesions that can be grouped into several targetable pathways, including Notch, Jak/Stat, PI3K/Akt/mTOR, and MAPK. With contemporary chemotherapy, outcomes for de novo T-ALL have steadily improved and now approach those observed in B-ALL, with approximately 85% 5-year event-free survival. Unfortunately, salvage has remained poor, with less than 25% event-free and overall survival rates for relapsed disease. Thus, current efforts are focused on preventing relapse by augmenting therapy for high-risk patients, sparing toxicity in favorable subsets and developing new approaches for the treatment of recurrent disease.

SUBMITTER: Raetz EA 

PROVIDER: S-EPMC6142501 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

T-cell acute lymphoblastic leukemia.

Raetz Elizabeth A EA   Teachey David T DT  

Hematology. American Society of Hematology. Education Program 20161201 1


T-cell acute lymphoblastic leukemia (T-ALL) is biologically distinct from its B lymphoblastic (B-ALL) counterpart and shows different kinetic patterns of disease response. Although very similar regimens are used to treat T-ALL and B-ALL, distinctions in response to different elements of therapy have been observed. Similar to B-ALL, the key prognostic determinant in T-ALL is minimal residual disease (MRD) response. Unlike B-ALL, other factors including age, white blood cell count at diagnosis, an  ...[more]

Similar Datasets

| S-EPMC6602906 | biostudies-literature
| S-EPMC5025801 | biostudies-other
| S-EPMC7569491 | biostudies-literature
| S-EPMC4662467 | biostudies-literature
| S-EPMC2847364 | biostudies-literature
| S-EPMC6277088 | biostudies-literature
| S-EPMC4548495 | biostudies-other
| S-EPMC2854430 | biostudies-literature
| S-EPMC6746003 | biostudies-literature
| S-EPMC5549947 | biostudies-literature